algenpantucel-l
Vaccineexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00255827)
Timeline
Indications
Mechanism of action
- Unspecified targetImmunity, active
immunity, active
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108717 ↗
Also known as
- algenpantucel-l
- hyperacute-pancreatic cancer vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02405585 | Phase 2 | Apr 1, 2015 | NewLink Genetics Inc |
| NCT01836432 | Phase 3 | May 1, 2013 | NewLink Genetics Inc |
| NCT01072981 | Phase 3 | Apr 1, 2010 | NewLink Genetics Inc |
| NCT00614601 | Phase 2 | Jan 1, 2008 | NewLink Genetics Inc |
| NCT00569387 | Phase 2 | Dec 1, 2007 | NewLink Genetics Inc |
| NCT00255827 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2005 | NewLink Genetics Inc, Northwestern University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NewLink Genetics Inc | For profit | 6 | 6 | 2 | 2005 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1